Bone densitometry manufacturer Norland Medical Systems saw its second-quarter revenues more than double compared with the first quarter of this year, but sales were still lower than in the second quarter of 1997. The White Plains, NY, company enjoyed a
Bone densitometry manufacturer Norland Medical Systems saw its second-quarter revenues more than double compared with the first quarter of this year, but sales were still lower than in the second quarter of 1997. The White Plains, NY, company enjoyed a 135% second-quarter increase in revenue over first quarter of the year, with sales of $4.8 million. That figure, however, fell 6% short of the $5.1 million in sales that the company recorded in the second quarter of 1997.
Norland reported a net loss for the quarter of $1.5 million, compared with net income of $195,000 in the second quarter of 1997. Although revenues are still lower than last year's levels, the company said that sales are rebounding for both peripheral and axial dual-energy x-ray absorptiometer (DEXA) products. Norland also reported healthy demand for its new Apollo DXA peripheral scanner (SCAN 6/10/98), although that system was not released in time to contribute much to the company's second-quarter results. Norland executives say the firm has sold more Apollo systems since the product's introduction than any other of its peripheral units.
Norland's revenue rebound was overshadowed by a pending decision from the NASDAQ Stock Market's delisting hearing panel on the company's market eligibility. Norland has run afoul of the exchange's $4 million net tangible assets requirement. The company met with the delisting panel on July 29 and is awaiting a decision on its NASDAQ status.
CT Study Reveals Key Indicators for Angiolymphatic Invasion in Non-Small Cell Lung Cancer
January 15th 2025In computed tomography (CT) scans for patients with solid non-small cell lung cancer (NSCLC) < 30 mm, emerging research suggests the lollipop sign is associated with a greater than fourfold likelihood of angiolymphatic invasion.
Can MRI-Based AI Enhance Risk Stratification in Prostate Cancer?
January 13th 2025Employing baseline MRI and clinical data, an emerging deep learning model was 32 percent more likely to predict the progression of low-risk prostate cancer (PCa) to clinically significant prostate cancer (csPCa), according to new research.
Shaping the Future of Radiology in 2025: Trends, Threats, and Opportunities
January 10th 2025How do we respond to challenges with staff recruitment, cybersecurity, and looming hospital takeovers in radiology? This author assesses key trends in radiology and offers key insights to stay competitive in the field.